<DOC>
	<DOC>NCT02091414</DOC>
	<brief_summary>This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant. The anticipated time on study treatment is 24 weeks.</brief_summary>
	<brief_title>A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; patients receiving their first heart transplant (single organ transplant). patients with a positive donorspecific crossmatch at the time of transplantation; patients with any antibodytreated acute rejection; known contraindications to treatment with sirolimus; history of malignancy, other than excised nonmelanoma skin cancer which has not recurred for 2 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>